Abstract: The invention relates to a microencapsulated insecticidal composition containing isopropyl (2E,4E)-3,7,11-trimethyl-11-methoxy-2,4-dodecaidenoate which comprises 45-95% by weight of isopropyl (2E,4E)-3,7,11-trimethyl-11-methoxy-2,4-dodecadenoate as active ingredient, 1-15% by weight of butyl hydroxy toluene and 5-40% by weight of activated charcoal, in the form of powdery microcapsules having a grain size of 1-300 .mu.m and coated with a hydroxypropyl methyl cellulose phthalate or cellulose acetate phthalate polymer.The advantage of the microencapsulated insectidical composition according to the present invention resides in the increased stability.

Abstract: The invention relates to a process for the preparation of sustained release solid pharmaceutical compositions having an active ingredient content of at least 80% and possessing a structure which loosens in aqueous medium but does not disintegrate to discrete particles within 4 hours which comprises coating the particles of the active ingredient in a liquid medium with a water insoluble polymer--preferably with an ethyl cellulose polymer film--and thereafter admixing the coated crystals with at least one disintegrating agent being capable of swelling in aqueous medium and other auxiliary agents conventionally used in pharmaceutical industry and pressing the mixture into tablets.The advantage of the process of the present invention is that it is readily feasible with a very wide range of active ingredients and provides sustained release tablets having a high active ingredient content.

Abstract: The invention relates to new plant growth regulating compositions, which contain as active agent 0.001 to 95% by weight of one or more compound(s) of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 each represent hydrogen atom, a C.sub.1-5 alkyl group, a C.sub.5-7 cycloalkyl group, an aryl group, a halogen-substituted aryl group, an aralkyl group, a C.sub.2-5 alkenyl group or a C.sub.2-5 alkynyl group, orR.sup.1 and R.sup.2 form, together with the adjacent nitrogen atom, a morpholino, pyrrolidino, piperidino or perhydroazepinyl group, andR.sup.3 stands for hydrogen or a C.sub.1-5 alkyl group,together with an inert, solid, liquid and/or gaseous carrier or diluent, and optionally one or more additives, such as surfactants or other substances of plant biological activity.The compounds of the general formula (I) in which R.sup.1 is hydrogen and R.sup.2 stands for hydrogen, C.sub.1-3 alkyl, aralkyl or C.sub.3-5 alkenyl group, furthermore in which R.sup.1 and R.sup.3 are hydrogen and R.sup.

Abstract: The invention relates to selected stereoisomers having the E, E or E, Z configuration and within the Formula (I) ##STR1## wherein N is 2-4, A is alkylene or 2 or 3 carbon atoms, R is phenyl or substituted phenyl and R.sup.1 and R.sup.2 are lower alkyl, or, together with the carbon to which attached, form a heterocyclic ring; and pharmaceutically acceptable acid addition salts thereof, a process for their preparation and pharmaceutical compositions comprising the same.The compounds of the general formula (I) can be used in therapy due to their narcosis potentiating, analgesic and antiarrhythmial effect.

Abstract: The invention relates to a process for the preparation of .alpha.- and .gamma.-interferon by isolating the buffy coat fraction of blood, removing the erythrocytes, suspending the leukocytes in a suitable nutrient medium and treating with an .alpha.-interferon inducer and with a .gamma.-interferon inducer, which comprises producing .alpha.-interferon and .gamma.-interferon one after the other in the same leukocyte culture by pre-treating the suspension obtained after the separation of the leukocyte/buffy coat/fraction of blood, removal of the erythrocytes and suspending the leukocytes in a suitable nutrient medium with - or .beta.-interferon, contacting with an .alpha.-interferon inducer, separating the liquid containing the .alpha.-interferon from the cells, if desired recovering the -interferon, washing and suspending the cells in a suitable nutrient medium, treating with a mitogenic agent, separating the liquid comprising .alpha.-interferon from the cells and if desired recovering .alpha.

Abstract: A one step process for the preparation of compounds having antidepressant activity of the formula I ##STR1## and isomers thereof, wherein R.sub.1, R.sub.2, Z and A.sup.- have the meanings indicated in the claims, which process comprises: heating a compound of the formula II ##STR2## wherein Z, A.sup.-, R.sub.1 and R.sub.2 have the meanings set out in the claims and R.sub.3 stands for hydrogen or C.sub.1-4 alkyl, in the presence of a dehydrating agent to split off a compound of the formula R.sub.3 OH. The invention is also directed to compounds of the formula I, wherein R.sub.2 is halogen and to compositions containing a compound of the formula I which exhibit antidepressant activity.

Abstract: The invention refers to a powder mixture having a high propylene glycol content and a process for the preparation thereof. The powder mixture consists of 25 to 75 percent by weight of propylene glycol and 75 to 25 percent by weight of magnesium oxide and/or magnesium peroxide and/or magnesium carbonate as a solid carrier(s). The powder mixture can be treated as a solid powder and it does not deliquesce in the air even when stored for a long time. The mixture can be used as solid propylene glycol in dietetic products for calf, piglet and lamb, in pharmaceutical compositions for the treatment of ketosis and in other pharmaceutical compositions for veterinary use.

Abstract: The invention relates to new carbazic acid derivatives, a process for the preparation thereof and compositions--particularly feed additives and animal feeds--containing the same. The new compounds according to the invention correspond to the formula (I)R.sup.1 .dbd.N--NH--COOR.sup.3 (I)wherein R.sup.1 stands for a C.sub.7-12 cycloalkylidene group, an indanylidene group or a group of the formula (IX) ##STR1## wherein A represents a phenyl group optionally carrying one or more identical or different substituents selected from the group consisting of halo, nitro, hydroxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, amino or C.sub.1-4 alkoxycarbonylhydrazino; phenyl-(C.sub.1-4 alkyl), C.sub.1-16 alkyl, C.sub.3-7 cycloalkyl or indolyl, or a C.sub.3 -C.sub.6 cycloalkyl group substituted by a C.sub.3 -C.sub.6 cycloalkyl group; R.sup.2 denotes a hydrogen atom, a C.sub.1-16 alkyl or a C.sub.3-7 cycloalkyl group; and R.sup.3 represents a C.sub.1-4 alkyl group.

Abstract: The invention relates to new N-substituted amino propane sulfonic acid derivatives of the Formula I ##STR1## and salts and hydrates thereof, a process for the preparation thereof and plant growth regulating agents comprising the same whereinR.sup.1 and R.sup.2 may be identical or different and stand for hydrogen, halogen, lower alkyl or lower alkoxy andR stands for furyl; or lower alkyl or phenyl the two latter groups being optionally substituted by one or more halogeno atom(s).

Abstract: The invention relates to new cycloalkane derivatives, a process for the preparation thereof and compositions--particularly feed additives and animal feeds--containing the same.The new compounds of the present invention correspond to the general formula I ##STR1## wherein n is 3, 4, 5 or 6;R denotes a phenyl group optionally carrying one or more substituent/s/ selected from the group consisting of halogen, lower alkoxy and lower alkyl;R.sup.1 and R.sup.2 each represent hydrogen or form together a valence bond;R.sup.3 represents lower alkoxy or a phenyl optionally substituted by one or more C.sub.1-12 alkoxy.The fodder additives and fodders according to the invention contain as active ingredient an amount of 1 ppm to 85% by weight of a compound of the general formula I in admixture with inert solid or liquid carriers or diluents and can be used to advantage in animal husbandry.

Abstract: The invention relates to new carbazic acid derivatives, a process for the preparation thereof and compositions--particularly feed additives and animal feeds--containing the same.The new compounds according to the invention correspond to the formula (I)R.sup.1 .dbd.N--NH--COOR.sup.3 (I)whereinR.sup.1 stands for a C.sub.7-12 cycloalkylidene group, an indanylidene group or a group of the formula (IX) ##STR1## wherein A represents a phenyl group optionally carrying one or more identical or different substituents selected from the group consisting of halo nitro, hydroxy, C.sub.1-14 alkoxy, C.sub.1-4 alkyl, amino or C.sub.1-4 alkoxycarbonylhydrazino; phenyl-(C.sub.1-4 alkyl), C.sub.1-16 alkyl, C.sub.3-7 cycloalkyl or indolyl or a C.sub.3 -C.sub.6 cycloalkyl group substituted by a C.sub.3 -C.sub.6 cycloalkyl group;R.sup.2 denotes a hydrogen atom, a C.sub.1-16 alkyl or a C.sub.3-7 cycloalkyl group; andR.sup.3 represents a C.sub.1-4 alkyl group.

Abstract: The invention relates to (E)-5-(2-bromovinyl)-uridine and its derivatives of general formula VI, ##STR1## wherein R.sup.1 stands for a hydrogen atom, C.sub.1-8 alkanoyl group, benzoyl group or a benzoyl group substituted in para position either with a C.sub.1-4 alkyl group or a halogen atom, and a process for preparing them by brominating 2',3',5'-tri-O-acyl-5-ethyl-uridine of general formula IV, ##STR2## wherein R is identical with R.sup.1, except where R.sup.1 stands for a hydrogen atom, dehydrohalogenating the resulting dibromo compound of general formula V ##STR3## and optionally deacylating it. The resulting compounds of general formula VI are exhibiting significant potency against Herpes simplex virus species and are of remarkably low acute toxicity.

Abstract: Pharmaceutical compositions for sustained release of pharmaceutical compounds comprising a reaction product of a water soluble salt of a pharmaceutically active compound containing a primary, secondary or tertiary amino group, and an alkali or ammonium salt of a synthetic copolymer containing an acid group, and selected from the group consisting of methacrylic acid/methacrylic acid methyl ester, methacrylic acid/acrylic acid methyl ester and methacrylic acid/acrylic acid methyl ester/methacrylic acid methyl ester copolymers and a pharmaceutically acceptable excipient. The water soluble salt of a pharmaceutically active compound containing a primary, secondary or tertiary amino group is reacted in aqueous medium with an alkali or ammonium salt of a copolymer selected from the group consisting of the above mentioned copolymers, and the resulting product is converted into a pharmaceutical composition.

Abstract: The invention relates to new 4-aryl-2-methyl-1,2,3,4-tetrahydro-isoquinoline derivatives of the general Formula I ##STR1## and salts thereof whereinR stands for hydrogen, lower alkyl or halogen andX represents a group of the general Formula --(CH.sub.2).sub.n --NR.sup.1 R.sup.2, --NH--R.sup.3 or --OR.sup.4, in whichR.sup.1 and R.sup.2 may be the same or different and stand for hydrogen or lower alkyl or R.sup.1 and R.sup.2 together with the adjacent nitrogen atom, they are attached to, form a 5- or 6-membered saturated heterocyclic ring which may optionally contain a further oxygen or sulfur atom or an optionally lower alkyl substituted imino group;n is an integral number 1, 2, 3 or 4;R.sup.3 stands for lower alkyl or optionally substituted phenyl andR.sup.4 is lower alkyl, halogeno lower alkyl, or phenyl lower alkyl.The compounds of the general Formula I are useful as antidepressants and antiparkinsone agents.The compounds of the general Formula I can be prepared by methods known per se.

Abstract: The invention relates to new cyclic imines of the general formula (I), ##STR1## wherein A represents carbonyl or hydroxymethylene,B is oxygen or imino,R stands for hydrogen or lower alkyl,X.sub.1 and X.sub.2 may be the same or different and represent hydrogen, halogen, lower alkyl or alkoxy, amino or nitro,n is 6 or 7, andm is 0 or 1,and pharmaceutically acceptable acid addition salts and quaternary salts thereof. The invention relates further to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds as the active ingredient and to a process for the preparation of said pharmaceutical compositions.The cyclic imine derivatives of the invention possess valuable antiarrhythmic properties and can be used to advantage in the treatment of cardiovascular diseases.

Abstract: The invention relates to new 2-hydroxymethyl-quinoxaline-1,4-dioxide derivatives of the general formula (I) ##STR1## wherein A represents an amino group, or a group of the general formula --NH--COOR.sub.1, wherein R.sub.1 stands for a C.sub.2-4 alkyl group, or a group of the general formula --NH--CX--NH.sub.2, whereinX denotes an oxygen or sulfur atom, or a group of the formula --NH--C(NH)--NH.sub.2, or a group of the general formula --NH--R.sub.2, wherein R.sub.2 represents a C.sub.1-6 alkyl, a phenyl, a benzyl, a hydroxyl or a hydroxy-(C.sub.2-4 alkyl) group, or a group of the general formula --NH--CO--R.sub.3, wherein R.sub.3 stands for a C.sub.1-20 alkyl group or a phenyl group optionally substituted by one, two or three identical or different substituent(s) selected from the group consisting of nitro, hydroxyl, amino, C.sub.1-3 alkoxy and halogen; a naphtyl group optionally substituted by a hydroxyl group, a phenyl-(C.sub.

Abstract: The invention relates to new bicyclo(2.2.1)heptane derivatives of the general formula I ##STR1## wherein R represents a C.sub.1-12 alkyl group optionally substituted by a lower alkoxy group, a C.sub.2-4 alkenyl group or a phenyl-(lower alkyl) group optionally substituted on (I), phenyl ring by one or more lower alkoxy groups or halogen atoms.The invention relates further to plant growth regulating compositions comprising as active agent 0.001 to 95% by weight of a racemic and/or optically active compound of the general formula I, wherein R has the above defined meanings, along with a conventional organic or inorganic, solid and/or liquid carrier and/or filler and/or diluent and/or surfactant.

Abstract: The invention relates to nitroalkanol derivatives of the general formula (I), ##STR1## wherein R.sub.1 is a C.sub.2-12 alkenyl or alkadienyl group, a C.sub.4-12 alkoxyalkyl or alkoxyalkenyl group having one or more C.sub.1-3 alkyl substituents, a C.sub.3-6 cycloalkyl or cycloalkenyl group, a furyl group, a nitrofuryl group, or a phenyl group having optionally one or more identical or different substituents selected from the group consisting of hydroxy, C.sub.1-4 alkoxy, halogen, nitro, C.sub.1-4 alkylenedioxy and C.sub.1-4 alkenoyloxy groups,R.sub.2 and R.sub.4 each represent hydrogen or they form together a valence bond,R.sub.3 is a C.sub.1-12 alkanoyloxy group, a benzoyloxy group having optionally one or more halogen substituents or hydrogen atom, andR.sub.5 is a C.sub.1-12 alkyl group or a phenyl group having optionally one or more halogen substituents,with the proviso that if R.sub.2 and R.sub.4 each stand for hydrogen, R.sub.1 is other than unsubstituted phenyl and R.sub.3 may represent only a C.sub.

Abstract: The invention relates to new bicyclo(2.2.1)heptane derivatives of the general formula I ##STR1## wherein R represents a C.sub.1-12 alkyl group optionally substituted by a lower alkoxy group, a C.sub.2-4 alkenyl group or a phenyl-(lower alkyl) group optionally substituted on the phenyl ring by one or more lower alkoxy groups or halogen atoms.The invention relates further to plant growth regulating compositions comprising as active agent 0.001 to 95% by weight of a racemic and/or optically active compound of the general formula I, wherein R has the above defined meanings, along with a conventional organic or inorganic, solid and/or liquid carrier and/or filler and/or diluent and/or surfactant.

Abstract: Acylated pyrido ?3,4-e!-as-triazines of the formula (I), ##STR1## wherein R.sub.1 stands for alkyl, alkoxy, haloalkyl, furyl, pyridyl, phenyl, phenyl-(C.sub.1-4 alkyl) or phyenyl-(C.sub.2-4 alkenyl) optionally substituted. R.sub.2 stands for hydrogen or a group of the formula R.sub.1 --CO--, R.sub.3 stands for hydrogen, a phenyl group or a naphthy6l group optionally substituted, or a phenyl-(C.sub.1-4 alkyl) group, pyridyl group or a C.sub.1-20 alkyl group, and R.sub.4 stands for hydrogen or a group of the formula R.sub.1 --CO--, and R.sub.5 forms together with R.sub.2 or R.sub.4 a valence bond, wherein R.sub.2 or R.sub.4 taking part in forming said valence bond may not have the above meaning, and pharmaceutically acceptable acid addition salts thereof, which are prepared by reacting a pyrido ?3,4-e!-as-triazine of the formula (II) or an acid addition salt thereof ##STR2## R.sub.6 stands for hydrogen, and R.sub.5 forms together with R.sub. and R.sub.